Triple malignancy: Sequential development of second and third primary tumors in a patient with Hodgkin's lymphoma

References

• Deniz K, O'Mahony S, Ross G, Purushotham A. Breast cancer in women after treatment for Hodgkin's disease. Lancet Oncol 2003; 4: 207–14
   PubMed Web of Science ®Google Scholar
• Wolden SL, Hancock SL, Carlson RW, et al. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000; 18: 765–72
   PubMedGoogle Scholar
• Ng A, Bernardo P, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 2002; 100: 1989–96
   PubMed Web of Science ®Google Scholar
• Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000; 48: 169–79
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063–73
   PubMed Web of Science ®Google Scholar
• Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V. Second solid tumors and leukaemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 1994; 29: 25–31
   PubMed Web of Science ®Google Scholar
• Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 732–41
   PubMed Web of Science ®Google Scholar
• Doria R, Holford T, Farber LR, Prosnitz LR, Cooper DL. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016–22
   PubMed Web of Science ®Google Scholar
• Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996; 14: 2435–43
   PubMed Web of Science ®Google Scholar
• Maurizi Enrici R, Anselmo AP, Osti MF, et al. Analysis of the risk of solid tumor following Hodgkin's disease. Haematologica 1997; 82: 57–63
   PubMedGoogle Scholar
• Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 2000; 18: 498–509
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487–97
   PubMed Web of Science ®Google Scholar
• Cellai E, Magrini SM, Masala G, et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: Analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 2001; 49: 1327–37
   PubMed Web of Science ®Google Scholar
• Dores G, Metayer C, Curtis E, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484–94
   PubMed Web of Science ®Google Scholar
• Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen?. Blood 1994; 84: 1209–15
   PubMed Web of Science ®Google Scholar
• Munker R, Grutzner S, Hiller E, et al. Second malignancies after Hodgkin's disease: The Munich experience. Ann Hematol 1999; 78: 544–54
   PubMedGoogle Scholar
• Chung CT, Bogart JA, Adams JF, et al. Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; 37: 405–9
   PubMed Web of Science ®Google Scholar
• Abrahamsen A, Andersen A, Nome O, Jacobsen A, Holte H, Abrahamsen J, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: The influence of treatment, age and follow-up time. Ann Oncol 2002; 13: 1786–91
   PubMedGoogle Scholar